personalized, responsive service and to improve the site, we remember and store information about how you use
Congratulations! You now have unlimited access to all articles from The Ophthalmologist.
Complete your profile at your earliest convenience to unlock the rest of your benefits:
relevant and personalised updates about your field
access to Case Studies/product profiles
digital magazine subscription
For our November issue, we set our sights on diabetes. In our cover feature, three “diabetic eye disease” gurus, Neil Bressler, Andrew Schimel and Heeral Shah, share their insights on the prevention, detection, diagnosis and treatment of diabetes-related disorders and discuss how treatments are going to evolve in the future. Anat Loewenstein calls for a systemic approach to these disorders, while Steve Charles argues that AI is not a serious solution to the tactical and strategic issues of the current diabetic retinopathy epidemic. We also delve into the new aflibercept regimen and discover how it can reduce the burden of treatment for many patients. The use of tear osmolarity and MMP-9 as the basis for an ocular surface disease treatment algorithm is also discussed, and piezo-print technology is highlighted as a potential solution for many of the issues associated with topical eye medications. Jennifer Stambook gives her take on how patient engagement needs to evolve in the digital age, while David Mandell and Carole Foos share the second part of their guide to building and protecting finances for mid-career ophthalmologists, and those approaching retirement. Finally, we sit down with Ravi Goel, ophthalmic surgeon at Wills Eye Hospital, USA.